Aurinia Discloses 2023 Year-End Financial and Operational Re

Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively



$350.7 million of...

Related Keywords

Canada , Rockville , Maryland , United States , Canadian , Peter Greenleaf , Joe Miller , Daniel Billen , Common Shares Of The Company , Drug Administration , European Commission , Exchange Commission Electronic Document Gathering , Aurinia Pharmaceuticals Inc , Company Annual Report On Form , Jp Morgan , Clinical Program , Nasdaq , Aurinia Pharmaceuticals , Full Year , Common Shares , Exemptive Relief , Common Share , Chief Financial Officer , Year Ended December , Annual Report , Canadian Securities Administrator System , Electronic Document Analysis , Exchange Commission , Electronic Document Gathering , Retrieval System , Markets ,